Original language | English (US) |
---|---|
Pages (from-to) | 779-782 |
Number of pages | 4 |
Journal | Journal of Hepatology |
Volume | 63 |
Issue number | 4 |
DOIs | |
State | Published - Oct 1 2015 |
Externally published | Yes |
Keywords
- Adherence
- Drug users
- HCV
- IFN-free
- Injecting
- Injection
- PWID
ASJC Scopus subject areas
- Hepatology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Excluding people who use drugs or alcohol from access to hepatitis C treatments - Is this fair, given the available data? / Grebely, Jason; Haire, Bridget; Taylor, Lynn E. et al.
In: Journal of Hepatology, Vol. 63, No. 4, 01.10.2015, p. 779-782.Research output: Contribution to journal › Editorial › peer-review
}
TY - JOUR
T1 - Excluding people who use drugs or alcohol from access to hepatitis C treatments - Is this fair, given the available data?
AU - Grebely, Jason
AU - Haire, Bridget
AU - Taylor, Lynn E.
AU - Macneill, Paul
AU - Litwin, Alain H.
AU - Swan, Tracy
AU - Byrne, Jude
AU - Levin, Jules
AU - Bruggmann, Philip
AU - Dore, Gregory J.
N1 - Funding Information: The Kirby Institute is funded by the Australian Government Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian Government. JG is supported by a National Health and Medical Research Council Career Development Fellowship. GD is supported by a National Health and Medical Research Council Practitioner Research Fellowship. LET is supported by the Lifespan/Tufts/Brown Center for AIDS Research (CFAR) P30AI042853 from the National Institute Of Allergy And Infectious Diseases and by an Innovation Fellowship by the Rhode Island Foundation. Funding Information: JG is a consultant/advisor and has received research grants from Abbvie, Bristol Myers Squibb, Gilead Sciences and Merck. GD is a consultant/advisor and has received research grants from Abbvie, Bristol Myers Squibb, Gilead, Merck, Janssen and Roche. LET has received research grants from Gilead. AL is a consultant/advisor and has received research grants from Gilead and Merck. PB is consultant/advisor and has received research grants from Abbvie, Bristol Myers Squibb, Gilead, Janssen and Merck.
PY - 2015/10/1
Y1 - 2015/10/1
KW - Adherence
KW - Drug users
KW - HCV
KW - IFN-free
KW - Injecting
KW - Injection
KW - PWID
UR - http://www.scopus.com/inward/record.url?scp=84941942912&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84941942912&partnerID=8YFLogxK
U2 - 10.1016/j.jhep.2015.06.014
DO - 10.1016/j.jhep.2015.06.014
M3 - Editorial
C2 - 26254264
AN - SCOPUS:84941942912
SN - 0168-8278
VL - 63
SP - 779
EP - 782
JO - Journal of Hepatology
JF - Journal of Hepatology
IS - 4
ER -